City
Epaper

EU authorizes AstraZeneca/Oxford COVID-19 vaccine

By IANS | Updated: January 30, 2021 14:00 IST

Brussels, Jan 30 The European Commission has granted conditional marketing authorization for the Covid-19 vaccine developed by British ...

Open in App

Brussels, Jan 30 The European Commission has granted conditional marketing authorization for the Covid-19 vaccine developed by British company AstraZeneca and Oxford University, although the bloc seems unlikely to get the amount of doses as agreed at the moment.

"Securing safe vaccines for Europeans is our utmost priority. With the AstraZeneca vaccine now authorized, 400 million additional doses will be available in Europe," European Commission President Ursula von der Leyen said on Friday.

Von der Leyen said that she expected AstraZeneca to deliver the doses as agreed so that Europeans can be vaccinated as soon as possible, reports Xinhua news agency.

"We will continue doing all we can to secure more vaccines for Europeans, our neighbors and our partners worldwide."

The European Union has been squabbling with the British company over the latter's announcement that it may deliver considerably fewer doses than promised for the first quarter.

The bloc published the contract with AstraZeneca on Friday, and meanwhile launched a transparency measure to regulate vaccines export from the union.

This is the third Covid-19 vaccine authorized in the EU, after Pfizer/BioNTech and Moderna vaccines were given the greenlights in late December and early January.

The authorization on Friday was granted hours after the European Medicines Agency (EMA) issued a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine.

Combined results from four clinical trials in the UK, Brazil and South Africa, involving around 24,000 people, showed that the vaccine was safe and effective in preventing Covid-19 in people from 18 years of age, according to the EMA.

Based on data relating to patients who received standard doses followed by second standard doses, the conclusion was drawn that the vaccine demonstrated nearly 60 percent efficacy in the clinical trials, it added.

( With inputs from IANS )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: ukEuropean CommissionBrusselsAstrazenecaUnion minister of healthUnion minister for healthJustice commissionState health directorateAstrazeneca plc.The european commission
Open in App

Related Stories

LifestyleGanpati Visarjan in London: Videos Show Indians Taking Out Ganesh Idol Immersion Procession With Band

MumbaiUniversity of Bristol Chooses Mumbai for Its First Overseas Campus, Set to Open in September 2026

NationalIndia Spends ₹1.38 Lakh Crore Annually on Edible Oil Imports

NationalTesla Model Y: Is It Cheaper in the US & China Than in India? Full Price Comparison Inside

InternationalUK to Ban Porn Featuring 'Choking' and 'Strangulation' Acts

Health Realted Stories

LifestyleToo Much Salt Is Not Just a Taste Problem It Could Signal Deeper Health Issues

HealthGlobal cholera crisis continues: 31 countries reported outbreaks in 2025, says WHO

HealthPfizer, Moderna shares slump as US govt plan to link Covid vaccines to child deaths: Report

HealthAiMeD welcomes govt’s GST rate cut, MRP implementation relief for medical devices

HealthPharmacopoeia Commission conducts training programme to boost regulation, quality of Ayush drugs